Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 16/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412088 | 1.00 | FAAH (0.65) | FAAHHSP90AA1KDM4EALDH1A1MAPT | |
| SCHEMBL4423387 | 1.00 | FAAH (0.65) | FAAHHSP90AA1KDM4EALDH1A1MAPT | |
| SCHEMBL4412272 | 1.00 | FAAH (0.65) | FAAHHSP90AA1KDM4EALDH1A1MAPT | |
| SCHEMBL4410614 | 1.00 | FAAH (0.65) | FAAHHSP90AA1KDM4EALDH1A1MAPT | |
| SCHEMBL4410939 | 1.00 | FAAH (0.65) | FAAHHSP90AA1KDM4EALDH1A1MAPT | |
| SCHEMBL4410267 | 1.00 | FAAH (0.65) | FAAHHSP90AA1KDM4EALDH1A1MAPT | |
| SCHEMBL4407217 | 0.99 | HSP90AA1 (0.65) | FAAHHSP90AA1KDM4EALDH1A1MAPT | |
| SCHEMBL4411378 | 0.97 | HSP90AA1 (0.68) | FAAHHSP90AA1KDM4EALDH1A1MAPT | |
| SCHEMBL4422323 | 0.92 | HSP90AA1 (0.68) | FAAHHSP90AA1KDM4EALDH1A1MAPT | |
| SCHEMBL6400230 | 0.88 | HSP90AA1 (0.65) | FAAHHSP90AA1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949574-B2 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | claimed |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2003-10-16 | — | — | US | claimed |
| US-20090082435-A1 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1472215-A4 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1742626-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | The Regents of The University of California (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006116773-A2 | METHODS, COMPOSITIONS, AND COMPOUNDS FOR MODULATION OF MONOACYLGLYCEROL LIPASE, PAIN, AND STRESS-RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2005115370-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-08 | — | — | WO | disclosed |
| US-6949574-B2 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050131032-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1472215-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003065989-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | FAAH, CNR2, FAAH2 | FAAH 1/4885HSP90AA1 616/4885KDM4E 3279/4885 |
| US-20090082435-A1 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders | MGLL, PNLIP, LIPC | FAAH 14/4885HSP90AA1 353/4885KDM4E 4120/4885 |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | FAAH 1/4885HSP90AA1 1769/4885KDM4E 450/4885 |
| US-20050131032-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | FAAH 1/4885HSP90AA1 1769/4885KDM4E 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.